Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
46,194
Total Claims
$11.5M
Drug Cost
1,204
Beneficiaries
$9,540
Cost/Patient
Risk Score Breakdown 32/100
Score components are additive. Read full methodology
Peer Comparison vs. 18,720 Cardiology providers
+526%
Cost per patient vs peers
$9,540 vs $1,524 avg
+204%
Brand preference vs peers
41.5% vs 13.7% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Cost per patient is 526% above the specialty average. Extreme cost outliers may indicate prescribing of unnecessarily expensive brand-name drugs or inappropriate drug utilization.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
0.1%
Opioid Rate
59
Opioid Claims
$547
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 19,145 claims · $10.1M
Generic: 26,972 claims · $1.4M
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Tirzepatide | 1,428 | $1.6M |
| Rivaroxaban | 1,621 | $1.0M |
| Icosapent Ethyl | 2,512 | $1.0M |
| Semaglutide | 804 | $834K |
| Pitavastatin Calcium | 1,617 | $596K |
| Azilsartan Medoxomil | 2,193 | $573K |
| Sacubitril/Valsartan | 624 | $486K |
| Lipase/Protease/Amylase | 330 | $382K |
| Evolocumab | 599 | $368K |
| Dapagliflozin Propanediol | 452 | $289K |
| Azilsartan Med/Chlorthalidone | 1,141 | $280K |
| Nebivolol Hcl | 2,902 | $248K |
| Semaglutide | 211 | $224K |
| Dexlansoprazole | 854 | $203K |
| Linaclotide | 341 | $197K |
Prescribing Profile
Patient Profile
80
Avg Age
63%
Female
1.70
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About